![](https://news.europawire.eu/wp-content/uploads/2023/09/novartis-pavillon-scaled-e1733739094175-144x144.jpg)
(IN BRIEF) Novartis has announced successful results from its Phase III NETTER-2 trial involving Lutathera, a treatment for neuroendocrine tumors (NETs). When used as a first-line treatment in combination with long-acting octreotide, Lutathera significantly improved progression-free survival in patients with … Read the full press release